| Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies R Benjamin, C Graham, D Yallop, A Jozwik, OC Mirci-Danicar, G Lucchini, ... The Lancet 396 (10266), 1885-1894, 2020 | 266 | 2020 |
| Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial MJ Frigault, J Dietrich, K Gallagher, M Roschewski, JT Jordan, D Forst, ... Blood, The Journal of the American Society of Hematology 139 (15), 2306-2315, 2022 | 80 | 2022 |
| UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a … R Benjamin, N Jain, MV Maus, N Boissel, C Graham, A Jozwik, D Yallop, ... The Lancet Haematology 9 (11), e833-e843, 2022 | 50 | 2022 |
| Acute kidney injury after the CAR-T therapy tisagenlecleucel MD Lee, IA Strohbehn, HS Seethapathy, N Rusibamayila, KS Casey, ... American Journal of Kidney Diseases 77 (6), 990-992, 2021 | 17 | 2021 |
| A phase II trial of anakinra for the prevention of CAR-T cell mediated neurotoxicity MJ Frigault, KME Gallagher, M Wehrli, B Valles, K Casey, K Lindell, ... Blood 138, 2814, 2021 | 10 | 2021 |
| Phase 1 study of CD37-directed CAR T cells in patients with relapsed or refractory CD37+ hematologic malignancies MJ Frigault, YB Chen, KME Gallagher, NK Horick, A El-Jawahri, I Scarfò, ... Blood 138, 653, 2021 | 9 | 2021 |
| Detection of CAR‐T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories U Johansson, K Gallagher, V Burgoyne, MV Maus, KS Casey, GG Brini, ... Cytometry Part B: Clinical Cytometry 100 (6), 622-631, 2021 | 6 | 2021 |
| Tisagenlecleucel demonstrates safety, efficacy and CNS trafficking in primary CNS lymphoma MJ Frigault, J Dietrich, KME Gallagher, I Scarfò, M Roschewski, JT Jordan, ... Blood 138, 258, 2021 | 4 | 2021 |
| Long: molecular tracking of CML with bilineal inv (16) myeloid and del (9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy V Venkataraman, KS Casey, M Onozato, PD Cin, V Nardi, PC Amrein, ... Leukemia 34 (11), 3050-3054, 2020 | 3 | 2020 |
| Clinical Features of AKI in Patients Receiving Tisagenlecleucel (CAR-T Therapy): PO2168 M Lee, IA Strohbehn, HS Seethapathy, N Rusibamayila, KS Casey, ... Journal of the American Society of Nephrology 31 (10S), 664, 2020 | | 2020 |
Matthew FrigaultMGH Cancer CenterVerified email at partners.org
